Evidence map›Paper›PMID 40734777›Full record

ArticleFrontiers in bioengineering and biotechnology2025

Correction: Baicalin-modifed polyethylenimine for miR-34a efficient and safe delivery.

Yingying Wang, Baiyan Wang, Yangfan Xiao, Qingchun Cai, Junyue Xing, Hao Tang, Ruiqin Li, Hongtao Zhang

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Yingying Wang *Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Baiyan Wang *Medical College, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Yangfan XiaoNational Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qingchun CaiDepartment of Clinical Lab, The Third Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
Junyue XingNational Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hao TangNational Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital and Central China Branch of National Center for Cardiovascular Diseases, Central China Fuwai Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ruiqin LiAcademy of Chinese Medicine, Henan University of Chinese Medicine, Zhengzhou, Henan, China.
Hongtao ZhangBlood Purification Center, The People's Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fbioe.2023.1290413.].

Indexed as

baicalingene therapyhydrophobic modificationlung cancermiR-34a

Identifiers

PMID40734777
PMCPMC12305337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.